Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor.

× No keyword cloud information.

25 in total

Review 1. SRC: a century of science brought to the clinic.

Authors: Alexey Aleshin; Richard S Finn
Journal: Neoplasia Date: 2010-08 Impact factor: 5.715

Review 2. Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors: Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal: Adv Drug Deliv Rev Date: 2017-04-25 Impact factor: 15.470

Review 3. Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia.

Authors: Emma H McCafferty; Sohita Dhillon; Emma D Deeks
Journal: Paediatr Drugs Date: 2018-12 Impact factor: 3.022

Review 4. Bone-targeting agents in prostate cancer.

Authors: Daniel L Suzman; Sosipatros A Boikos; Michael A Carducci
Journal: Cancer Metastasis Rev Date: 2014-09 Impact factor: 9.264

5. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.

Authors: Y-C Lee; C-F Huang; M Murshed; K Chu; J C Araujo; X Ye; B deCrombrugghe; L-Y Yu-Lee; G E Gallick; S-H Lin
Journal: Oncogene Date: 2010-03-15 Impact factor: 9.867

Review 6. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.

Authors: John Araujo; Christopher Logothetis
Journal: Cancer Treat Rev Date: 2010-03-11 Impact factor: 12.111

7. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.

Authors: Daniela Hoehn; Jorge E Cortes; L Jeffrey Medeiros; Elias J Jabbour; Juliana E Hidalgo; Rashmi Kanagal-Shamanna; Carlos E Bueso-Ramos
Journal: Clin Lymphoma Myeloma Leuk Date: 2016-08

8. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.

Authors: Teresa Di Desidero; Paola Orlandi; Daniela Gentile; Marta Banchi; Greta Alì; Claudia Kusmic; Paolo Armanetti; Ginelle J Cayme; Luca Menichetti; Gabriella Fontanini; Giulio Francia; Guido Bocci
Journal: Pharmacol Res Date: 2020-05-24 Impact factor: 7.658

9. NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF-κB.

Authors: Hengwei Zhang; Matthew J Hilton; Jennifer H Anolik; Stephen L Welle; Chen Zhao; Zhenqiang Yao; Xing Li; Zhiyu Wang; Brendan F Boyce; Lianping Xing
Journal: J Clin Invest Date: 2014-06-02 Impact factor: 14.808

10. Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.

Authors: Teresa Di Desidero; Alessandro Antonelli; Paola Orlandi; Silvia Martina Ferrari; Anna Fioravanti; Greta Alì; Gabriella Fontanini; Fulvio Basolo; Giulio Francia; Guido Bocci
Journal: Cancer Lett Date: 2017-09-28 Impact factor: 8.679